Technologies accelerating engineering into advanced modalities
17 Jun 2024
Salon D
Bi/Multispecifics
){kind=logo}
- Common Light Chain discovery approaches, advantages, and limitations
- Single Domain Antibodies: what we have learned so far about VHHs, discovery platforms, reformatting, physicochemical properties
- Bi-specifics vs CARs – the battle of biologics modalities: is there going to be only one winner?
